Navigation Links
Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
Date:7/9/2008

SOUTH SAN FRANCISCO, July 9 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc., announced today it has initiated a Phase II proof-of-concept study of Simulect(R) (basiliximab) for the treatment of noninfectious uveitis, a chronic and potentially sight-threatening inflammation of the eye. The randomized, double-masked, placebo-controlled study will evaluate the safety and efficacy of Simulect as maintenance therapy in 56 patients. During the study, patients will undergo tapering of concomitant immunosuppressive medications, the mainstay of treatments for noninfectious uveitis. This is the second mid-stage trial for basiliximab run by Cerimon, which began a Phase IIb study for patients with moderate-to-severe, steroid-refractory ulcerative colitis (UC) in April 2007.

"The initiation of this proof-of-concept study is part of our overall strategy to seek additional indications for already marketed drugs in areas with significant unmet medical needs," stated Paul Sekhri, President and CEO of Cerimon Pharmaceuticals. "In noninfectious uveitis, we believe Simulect has the potential to significantly improve the quality of life for patients by reducing adverse events often associated with oral or topical corticosteroids while maintaining effective control of their inflammation."

Basiliximab is a monoclonal antibody that selectively blocks the interleukin-2 (IL-2) receptor. This mechanism of action provides highly targeted inhibition of the T-lymphocyte activation that is involved in serious immune-related diseases including noninfectious uveitis. In February 2006, the Company licensed basiliximab from Novartis Pharma AG for the treatment of Inflammatory Bowel Disease (IBD) and initiated a Phase IIb clinical study for the treatment of moderate-to-severe, steroid-refractory ulcerative colitis the following year. In December 2007, Cerimon entered into an agreement with Novartis to conduct a proof-of-concept study for basiliximab for the treatment of noninfectiou
'/>"/>

SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
2. Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch
3. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
4. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
7. Isis Pharmaceuticals Conference Call Notice
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
10. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
11. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 , La ... contribuye a adquirir tolerancia a la proteína de ... proteína de la leche de la vaca (APLV) es la ... Hasta ahora, la APLV se trataba eliminando las ... demostrado que es posible adquirir tolerancia oral en ...
(Date:10/30/2014)... SAN FRANCISCO , Oct. 30, 2014 /PRNewswire/ ... rehydration solution (ORS), announced that it was awarded ... the leading healthcare services company that serves the ... Inc., UHC, Children,s Hospital Association and Provista.  ... designation based on feedback from member hospitals who ...
(Date:10/30/2014)... , Oct. 29, 2014 nebulizer is ... disorders (asthma, COPD and cystic fibrosis) that converts liquid ... easily reach into the lungs of a patient when ... global nebulizers market is dominated by various devices powered ... increasing prevalence of asthma, COPD and cystic fibrosis and ...
Breaking Medicine Technology:Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 2DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 4Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3
... 2010 Palatin Technologies, Inc. (NYSE Amex: PTN ... (the "Exchange"), advising Palatin that it is not in compliance ... Section 1003 of the Exchange,s Company Guide. In ... not in compliance with Section 1003(a)(iii) of the Company Guide ...
... 2, 2010 The Harley Medical Group is reporting a ... as an early present for themselves, the month before Christmas. ... to ensure a full recovery is made before they return ... procedures for Christmas 2010 include: Breast enlargement , Nose ...
Cached Medicine Technology:Palatin Technologies Receives Non-Compliance Letter from NYSE Amex 2Palatin Technologies Receives Non-Compliance Letter from NYSE Amex 3The Harley Medical Group Sees an Uptake in Surgery Bookings for Christmas 2
(Date:10/30/2014)... October 30, 2014 Five months after ... Hodgkinson Street LLC announces new branding and a website ... Mepham . After David Mepham’s promotion to name partner ... and website to include Mepham’s name and better reflect ... and mediation firm, the decision to implement new branding ...
(Date:10/30/2014)... Haelle HealthDay Reporter , ... 100 genes have been identified that appear linked to ... researchers say they are on their way to discovering ... the disorder. Autism spectrum disorders include a range ... and repetitive behaviors. An estimated one in 68 U.S. ...
(Date:10/30/2014)... Global prebiotics market is expected to reach ... study by Grand View Research, Inc. Positive outlook on ... fat free products owing to increased concerns over obesity ... the forecast period. , View full report with TOC ... was the largest application segment with market volume of ...
(Date:10/30/2014)... The Woodlands, TX (PRWEB) October 30, 2014 ... hospital system, released today its 2014 third quarter ... hospitals across Texas boasted infection rates of only ... also reported patient satisfaction scores exceeding 98 percent. ... this past quarter, which included rising satisfaction scores,” ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... lots of milk could be bad for your health, a ... calcium in milk can help strengthen bones and prevent osteoporosis. ... to recommend milk as part of a healthy diet. ... milk did not protect men or women from bone fractures, ...
Breaking Medicine News(10 mins):Health News:Hodgkinson Street Mepham Rebrands 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3
... , PITTSBURGH, July 27 Childhood obesity ... adults and can lead to premature death in adulthood due ... In addition to its significant human toll, childhood obesity alone ... , , To address the continued tide ...
... survey of men who opt out of aggressive treatment ... delay treatment for their early prostate cancer are not ... research shows. , The evidence seems to contradict the ... for most patients, according to Dr. Roderick van den ...
... YORK, July 27 Paradigm Spine, LLC, a developer of ... a $21.5 million financing, consisting of a $15mm debt facility ... lender in the $15mm venture debt funding. The $6.5 ... asset management group specializing in high-growth opportunities, and Trevi Health ...
... ... upcoming Materials and Processes for Medical Devices Conference , Aug. 10-12 at the Hilton ... (Vocus) July 27, ... upcoming Materials and Processes for Medical Devices Conference , Aug. 10-12 at the Hilton ...
... , , , ... tell people,s personalities based on the types of drink they enjoy. ... as sweet and indulgent, while someone who likes fruity drinks could be ... Angeles-based BLD & Grace Restaurants says the same could be said for ...
... Spanish . Capsule endoscopy for exploring ... all lesions located by means of conventional colonoscopy. According to ... Medicine the specialised medical journal with greatest international ... achieve similar efficacy to the conventional procedure undertaken with a ...
Cached Medicine News:Health News:Highmark Provides Pediatricians With Resources to Combat Childhood Obesity 2Health News:Highmark Provides Pediatricians With Resources to Combat Childhood Obesity 3Health News:Most Not Worried by Delayed Prostate Cancer Therapy 2Health News:Paradigm Spine Closes $21.5 Million Financing and Announces Promotion of Matt Stuttle to Position of Vice President, US Sales 2Health News:Paradigm Spine Closes $21.5 Million Financing and Announces Promotion of Matt Stuttle to Position of Vice President, US Sales 3Health News:Minnesotans to Keynote Materials for Medical Devices Conference 2Health News:Personality in a Cup 2Health News:Personality in a Cup 3Health News:Colon capsule endoscopy diagnoses 64 percent of total polyps detected by conventional colonoscopy 2Health News:Colon capsule endoscopy diagnoses 64 percent of total polyps detected by conventional colonoscopy 3Health News:Colon capsule endoscopy diagnoses 64 percent of total polyps detected by conventional colonoscopy 4Health News:Colon capsule endoscopy diagnoses 64 percent of total polyps detected by conventional colonoscopy 5
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: